New Blood Test Detects Alzheimer's Tau Tangles Better Than Existing Markers

Tau neurofibrillary tangles are a defining feature of Alzheimer's disease and correlate more closely with clinical symptoms and cognitive decline than amyloid plaques. While tau-PET imaging can detect these aggregates, it requires expensive infrastructure available only at specialized centers. Existing blood and CSF biomarkers such as p-tau181 and p-tau217, though widely used, predominantly reflect amyloid plaque burden and soluble tau phosphorylation — not actual insoluble tau aggregates — limiting their utility for tracking tangle pathology or evaluating tau-directed therapies.

This study introduces plasma eMTBR-tau243, an endogenously cleaved tau peptide from the microtubule-binding region containing residue 243, measured using a highly sensitive mass spectrometry-based assay. The biomarker was developed and validated across three independent cohorts: a discovery cohort (n=108) from Washington University, a replication cohort (n=55), and a large validation cohort (n=739) from Lund University's BioFINDER study. Participants spanned the full Alzheimer's spectrum from cognitively unimpaired amyloid-negative individuals through preclinical AD, MCI, and AD dementia, as well as non-AD cognitive impairment groups.

Plasma eMTBR-tau243 levels were significantly elevated beginning at the MCI stage in amyloid-positive individuals and increased further in those with AD dementia. Crucially, the biomarker showed strong associations with tau-PET binding across Braak regions (β=0.72, R²=0.56), substantially outperforming plasma %p-tau217 (R²=0.44) and %p-tau205 in the same models. Its association with cognitive performance as measured by the Mini-Mental State Examination was also superior (β=0.60, R²=0.40 versus R²=0.28 for %p-tau217). Importantly, eMTBR-tau243 showed weaker associations with amyloid-PET than existing markers, confirming its specificity for tau tangle pathology rather than upstream amyloid changes.

The clinical implications are substantial. Because p-tau species respond to anti-amyloid immunotherapies even when tau aggregates remain unchanged, they are poor monitors for tau-targeted treatments. Plasma eMTBR-tau243, by specifically tracking insoluble tangles, could serve as a pharmacodynamic biomarker in anti-tau clinical trials. It could also help identify symptomatic patients whose cognitive impairment is directly attributable to tau tangle burden — a distinction critical for predicting who will benefit most from anti-amyloid or anti-tau therapies. The blood-based format makes it far more scalable than PET or lumbar puncture-based CSF testing.

Caveats include the assay's current reliance on mass spectrometry, which requires specialized equipment not yet standard in clinical laboratories. Cross-sectional design limits causal inference about longitudinal tangle progression. Validation in more diverse populations and head-to-head comparisons with emerging immunoassay platforms will be needed before widespread clinical adoption.